| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-305SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-1604-0.05ml | |||
HAF008). For additional reference, Recombinant Human Active ERK1 (Catalog # 1879-KS) and Recombinant Human Active ERK2 (Catalog # 1230-KS) (2 ng/lane) were included. A specific band for ERK1/ERK2 was detected at approximately 44 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." alt="Western blot shows lysates of Jurkat human acute T cell leukemia cell line, C2C12 mouse myoblast cell line myoblast cell line, and C6 rat glioma cell line. PVDF membrane was probed with 0.2 µg/mL Rabbit Anti-Human/Mouse/Rat ERK1/ERK2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1576) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). For additional reference, Recombinant Human Active ERK1 (Catalog # 1879-KS) and Recombinant Human Active ERK2 (Catalog # 1230-KS) (2 ng/lane) were included. A specific band for ERK1/ERK2 was detected at approximately 44 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_thumb" />
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF1576-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-29883-0.025ml | |||
![Immunohistochemistry-Paraffin: Neuromedin S Antibody [NBP3-42326] - Used in DAB staining on fromalin fixed paraffin-embedded Brain tissue](http://images.novusbio.com/fullsize/nbp3-42326_rabbit-neuromedin-s-pab-612202421195643.jpg "Immunohistochemistry-Paraffin: Neuromedin S Antibody [NBP3-42326] - Used in DAB staining on fromalin fixed paraffin-embedded Brain tissue")
![Western Blot: Neuromedin S Antibody [NBP3-42326] - Sample: Recombinant protein.](http://images.novusbio.com/fullsize/nbp3-42326_rabbit-neuromedin-s-pab-61220242195731.jpg)
![Western Blot: Neuromedin S Overexpression Lysate (Adult Normal) [NBP2-11002] Left-Empty vector transfected control cell lysate (HEK293 cell lysate); Right -Over-expression Lysate for Neuromedin S.](http://images.novusbio.com/fullsize/Neuromedin-S-Overexpression-Lysate-Adult-Normal-Western-Blot-NBP2-11002-img0001.jpg "Western Blot: Neuromedin S Overexpression Lysate (Adult Normal) [NBP2-11002] Left-Empty vector transfected control cell lysate (HEK293 cell lysate); Right -Over-expression Lysate for Neuromedin S.")
![Western Blot: Neuromedin S Antibody [H00129521-B01P-50ug] - Analysis of NMS expression in transfected 293T cell line by NMS MaxPab polyclonal antibody. Lane 1: NMS transfected lysate(16.83 KDa). Lane 2: Non-transfected lysate.](http://images.novusbio.com/fullsize/Neuromedin-S-Antibody-Western-Blot-H00129521-B01P-50ug-img0001.jpg "Western Blot: Neuromedin S Antibody [H00129521-B01P-50ug] - Analysis of NMS expression in transfected 293T cell line by NMS MaxPab polyclonal antibody. Lane 1: NMS transfected lysate(16.83 KDa). Lane 2: Non-transfected lysate.")
![Immunocytochemistry/Immunofluorescence: 53BP1 Antibody [NB100-305] - NIH3T3 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NB100-305 at 2 ug/mL overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse DyLight 550 (Red) at a 1:1000 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/53BP1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-305-img0010.jpg "Immunocytochemistry/Immunofluorescence: 53BP1 Antibody [NB100-305] - NIH3T3 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NB100-305 at 2 ug/mL overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse DyLight 550 (Red) at a 1:1000 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.")
![Immunohistochemistry: 53BP1 Antibody [NB100-305] - Immunohistochemical staining of placental villi with 53BP1 Antibody (Catalog #NB100-305) at 40X magnification.](http://images.novusbio.com/fullsize/53BP1-Antibody-Immunohistochemistry-NB100-305-img0005.jpg)
![Western Blot: 53BP1 Antibody [NB100-305] - Western blot of whole cell lysate (20 ug/lane) from U2Os cells resolved on a 3 to 8 percent trisacetate gel. A band appears at approximately the theoretical molecular weight of 214 kDa.](http://images.novusbio.com/fullsize/53BP1-Antibody-Western-Blot-NB100-305-img0004.jpg)
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: 53BP1 Antibody [NB100-305] - HCC1937 cells (human) were treated with PARPi for 96 h. Nuclei are stained in blue (DAPI) and 53BP1 antibody (foci in green). ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/53BP1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-305-img0012.jpg)
![Flow Cytometry: 53BP1 Antibody [NB100-305] - An intracellular stain was performed on Ntera2 cells with 53BP1 Antibody NB100-305 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/53BP1-Antibody-Flow-Cytometry-NB100-305-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: 53BP1 Antibody [NB100-305] - Paraformaldehyde (4%) fixed Saos-2 cells (human osteosarcoma cell line) were stained with anti-53BP1 antibody followed by Alexa Fluor 488 secondary antibody. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/53BP1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-305-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: 53BP1 Antibody [NB100-305] - Ntera2 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NB100-305 at 2 ug/mL overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse DyLight 550 (Red) at a 1:1000 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/53BP1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-305-img0009.jpg)
![Flow Cytometry: 53BP1 Antibody [NB100-305] - An intracellular stain was performed on HeLa cells with 53BP1 Antibody (Catalog #NB100-305AF488) (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/53BP1-Antibody-Flow-Cytometry-NB100-305-img0006.jpg)
![Western Blot: 53BP1 Antibody - BSA Free [NB100-305] - DNA damage & DNA damage responses upon H2O2 challenge. a, c, e, g Confocal images showing the basal region of the organ of Corti cultures treated with either culture medium alone (a, e) or containing 0.5 mM H2O2 (c, g) for 5 h before being maintained in culture medium alone for 3 days. The samples were then immunolabeled for myosin 7A (red, a, c, e, g), gamma H2AX (green, a & c) & 53BP1 (green, e & g). Scale bars: a, c, e & g = 10 μm. b, d, f, h Higher magnification images of representative OHC & IHC nuclei from all conditions tested. Scale bar = 2.5 μm. i Representative Western blot analysis using antibodies against gamma H2AX, 53BP1, DDB2, p-Chk1, p-Chk2, p53, & beta -actin in whole cochlear extracts. j, k Histograms representing the levels of gamma H2AX, 53BP1, DDB2, p-Chk1, p-Chk2, & p53 in control & in 0.4 & 0.5 mM H2O2-exposed groups (n = 6 cochleae per condition). beta -Actin served as a loading control. Data are expressed as mean ± SEM. One-way ANOVA test followed by post hoc Tukey’s test (*P ≤ 0.04, **P ≤ 0.01, ***P ≤ 0.001 vs. H2O2 0 mM). All experiments were performed in triplicate Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30693443), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-305_rabbit-polyclonal-53bp1-antibody-310202415532062.jpg)
![Western Blot: 53BP1 Antibody - BSA Free [NB100-305] - Assessment of satellite cell radiosensitivity & DNA repair pathways w/ age.(A–B) Expression of major proteins involved in homologous recombination & non-homologous end joining detected using WB. Protein nuclear extracts prepared from activated satellite cells 72 hrs post muscle injury. Lamin B used as loading control. (A) Representative images of WBs. (B) Quantification using Image J software. Data represents mean +/− SEM, n = 3 to 5 (n = a pool of muscles from 3 mice), 2-tailed unpaired Student's t-test, no significant difference. (C) Graphical representation of data from Table S1. Gene expression of old relative to young satellite cells presented as fold change w/ a 95 % confidence interval for the 12 genes w/ a statistically significant relative expression, n = 3 mice per group, two-tailed unpaired Student's t-test, *: p value<0.05. Dotted line represents young level. BER: Base Excision Repair, NER: Nucleotide-Excision Repair; MR: Mismatch Repair, DRR: DNA Repair Related. (D–E) Satellite cells freshly isolated from uninjured (D) or 72 hrs after injury (E) muscle of C57BL/6 young & old mice, & of young SCID mice. Cells plated at low density, irradiated at indicated Gray (Gy) doses, & cultured for 10 days. Myogenic colonies formed by irradiated cells quantified & represented relative to ir respective non-irradiated controls. On average, 178, 77, & 228 myogenic colonies scored per mouse for young, old, & SCID uninjured non-irradiated respectively & 67, 34, & 91 myogenic colonies scored per mouse for young, old, & SCID injured non-irradiated respectively. Data represent mean +/− SEM, n = 3 to 4 mice per group, two-tailed unpaired Student's t-test, a, b or c: p value<0.05, (a: young vs old, b: young vs SCID, c: old versus SCID). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23704914), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-305_rabbit-polyclonal-53bp1-antibody-31020241553204.jpg)
![Exosomes modulate the repair of DNA DSBs in irradiated recipient cells.(A) Number of 53BP1 foci in BHY cells 1 hour after irradiation with 0 and 2 Gy and transfer of BHY exosomes isolated 24 hours after irradiation with 0 and 6 Gy [n = 5]. (B) Representative images of 53BP1 foci in BHY cells 6 hours after 2 Gy and transfer of BHY exosomes isolated 24 hours after irradiation with 0, 3, 6 or 9 Gy (53BP1 foci green, nuclei blue). (C) Number of 53BP1 foci in BHY cells 6 hours after 2 Gy and transfer of BHY exosomes isolated 24 and 48 hours after irradiation [n1 (control; EXO 0 Gy 24 h; EXO 6 Gy 24 h) = 6, n2 (EXO 0 Gy 48 h; EXO 3 Gy; EXO 6 Gy 48 h; EXO 9 Gy) = 3]. (D) Number of 53BP1 foci in FaDu cells 6 hours after 2 Gy and transfer of FaDu exosomes [n = 3]. (E) Number of 53BP1 foci in FaDu cells 6 hours after 2 Gy and transfer of BHY exosomes [n = 3]. (F) Number of 53BP1 in BHY cells after 2 Gy and transfer of destabilized BHY exosomes. Exosomes from BHY cells isolated 24 hours after irradiation with 0 and 6 Gy were treated with RNase A or a mixture of Triton and Trypsin [n1 (control; intact) = 6; n2 (RNase A 5 μg/μl) = 2; n3 (RNase A 400 μg/μl; Triton + Trypsin) = 3]. For all experiments the +/- SD was shown and p-values calculated on control were considered to be significant if * p < 0.05 and highly significant ** if p < 0.01, while ▲ p < 0.05 and ▲▲ p < 0.01 indicate significant differences to EXO 0 Gy. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/27006994), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-305_rabbit-polyclonal-53bp1-antibody-immunocytochemistry-immunofluorescence-13220261941180.jpg)
![Immunohistochemistry-Frozen: Nestin Antibody [NB100-1604] - Analysis of Nestin in frozen mouse tissue using anti-Nestin antibody. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Nestin-Antibody-Immunohistochemistry-Frozen-NB100-1604-img0001.jpg)
![Immunocytochemistry/ Immunofluorescence: Nestin Antibody [NB100-1604] - In vitro proliferation & differentiation of ahMNCs-Clump II. (A) ahMNCs-Clump II were propagated in the culture condition for ahMNCs. The accumulated number of cells of ahMNCs-Clump II (NS18-007TL & 008TL) in comparison with ahMNCs established using previous culture methods (NS14-010TL, NS14-011TL, & NS15-001TL). Days to 1 × 109 cells are indicated. (B) Morphologies of ahMNCs-Clump II under expansion processes are illustrated until third in vitro passage (P3). Scale bar = 50 μm. (C) After in vitro differentiation, immunofluorescence was applied to ahMNCs-Clump II. Nestin for NSCs, MAP2 & Tuj1 for neurons, & GFAP for astrocytes. Undiffer = before in vitro differentiation; Differ = after in vitro differentiation. Scale bar = 10 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30380605), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1604_chicken-polyclonal-nestin-antibody-310202415291944.jpg)
![Immunocytochemistry/ Immunofluorescence: Nestin Antibody [NB100-1604] - Representative images of nestin (A) & Tmsb4x (B) staining in the mouse adult wild-type glomerulus visualized by fluorescent microscopy. (C) Merged images showing Tmsb4x (red) & nestin (green) staining; areas of colocalization are indicated by arrows. Representative images of Tmsb4x (D) & Cd31 (E) staining in the mouse adult wild-type glomerulus visualized by fluorescent microscopy. (F) Merged images showing Tmsb4x (green) & Cd31 (red) staining. Bar = 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27575556), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1604_chicken-polyclonal-nestin-antibody-310202415304248.jpg)
![Immunocytochemistry/ Immunofluorescence: Nestin Antibody [NB100-1604] - Dopaminergic neuron derivation from H9 stem cells & hIPSCs.Scheme showing the different steps of the DA neuron derivation protocol (A). Immunolabelings of cultured H9 (top panels) & WT hiPSCs (bottom panels) for different NSCs markers, Sox1, Pax6 & Nestin (B). Immunolabeling of cultured H9 (top panels) & WT hiPSCs (bottom panels) after 3 days of DA progenitor induction for progenitor markers Lmx1A & FoxA2 (C) & after 7 days of induction for immature neurons beta III-Tubulin+ & remaining progenitors Sox1+ (D). Immunolabelings of cultured H9 (top panels) & WT hiPSCs (bottom panels) after 21 days of induction for the neuronal marqueur MAP2 & DA neurons Tyrosine Hydroxylase (TH) (E). Analysis of gene expression levels by qRT-PCR for cultured H9 (top panels) & WT hiPSCs at different time points (NSC, 14 days & 21 days) of the culture (FB = fetal brain) (F,G). Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/srep33377), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1604_chicken-polyclonal-nestin-antibody-31020241555236.jpg)
![Immunocytochemistry/ Immunofluorescence: Nestin Antibody [NB100-1604] - Neural Stem Cell derivation from WT & LRRK2 G2019S hiPSCs.Haematoxylin & eosin coloration of teratoma-encapsulated tumors generated by flank injection of WT & G2019S hiPSCs cells in Nod/Scid mice. Representative images of the different germ layers: ectoderm (immature squamous epithelium, neural rosettes), mesoderm (primitive cartilage, muscles, fat) & endoderm (primitive gut like epithelium) (A). Scheme showing the different steps of the DA neuron derivation protocol (B). Immunolabelings of cultured WT & LRRK2 G2019S hIPSCs for different NSCs markers after NSCs induction protocol: Sox1, Nestin, Pax6 & Ki67 (C). Analysis of gene expression levels by qRT-PCR for WT & LRRK2 G2019S cultures at the end of the NSCs induction protocol (D). Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/srep33377), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1604_chicken-polyclonal-nestin-antibody-31020241554536.jpg)
![Immunocytochemistry/ Immunofluorescence: Nestin Antibody [NB100-1604] - PAR1 is expressed by neural stem cells in the sub-ventricular zone (SVZ) of the adult mouse brain. Photomicrographs show immunofluorescence double-labeling for PAR1 with Sox2-positive (A), or PAR1 with Nestin-positive (C) multipotent neural stem cells (NSCs) within the lateral wall of the lateral ventricle (LV). RNAscope was used to identify cells expressing both PAR1 & Sox2 (B), or Nestin (D) RNA in NSCs of the adult SVZ. Arrow indicates an example of a double-labeled cell in each case, with arrowhead indicating a singly labeled cell (Scale bar = 10 μm). Boxed area in B & D is also shown at higher magnification to visualize double-labeled cells. (E) Histogram shows expression of PAR1 RNA was high in NSCs grown as neurospheres (NS), or when plated on poly-L-lysine coated coverslips as monolayers in stem cell media containing EGF & bFGF. PAR1 RNA expression by NSC monolayers decreased by 87% when EGF & bFGF were removed from the media for 7 DIV promoting stem cell differentiation. (F) Withdrawal of EGF & bFGF to induce NSC monolayer differentiation resulted in a parallel decrease in Nestin RNA expression. (**P < 0.01, ***P < 0.001 Students t-test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29921916), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1604_chicken-polyclonal-nestin-antibody-31020241612687.jpg)
![Immunohistochemistry-Frozen: Rabbit IgG Isotype Control [NB810-56910] - Mouse ear skin (aceton-fixed frozen section) stained with rabbit IgG isotype control, which was used as a negative control. Image from verified customer review.](http://images.novusbio.com/fullsize/Rabbit-IgG-Isotype-Control-Immunohistochemistry-Frozen-NB810-56910-img0012.jpg "Immunohistochemistry-Frozen: Rabbit IgG Isotype Control [NB810-56910] - Mouse ear skin (aceton-fixed frozen section) stained with rabbit IgG isotype control, which was used as a negative control. Image from verified customer review.")
![Immunohistochemistry-Frozen: Rabbit IgG Isotype Control [NB810-56910] - Mouse ear skin (aceton-fixed frozen section) stained with rabbit IgG isotype control, which was used as a negative control. Image from verified customer review.](http://images.novusbio.com/fullsize/Rabbit-IgG-Isotype-Control-Immunohistochemistry-Frozen-NB810-56910-img0011.jpg)
![Western Blot: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Image from verified customer review. Image using the HRP form of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-Fc-Secondary-Antibody-Western-Blot-NB7446-img0001.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416154644.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416165644.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416154630.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416175295.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416163732.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416171447.jpg)
